Background: For advanced rectal cancer with involved or threatened mesorectal fascia (MRF), current standard is pre-operative long course chemoradiotherapy (PLCRT) with either capecitabine or 5-fluorouracil (5-FU). However, few Chinese data on its clinical outcome are available, especially for those with pelvic MRI staging. Methods: Between Jan-2009 and Oct-2014, 123 consecutive patients with biopsy proven adenocarcinoma of rectum, all with pelvic MRI staging, selected for PLCRT after multidisciplinary team discussion were recruited. Their clinical records were retrospectively reviewed. Results: Median follow-up was 1392 days (range: 48e2886) MRI defined poor risk factors as follows: MRF threatened or involved 1 mm 61.8% (n Z 76), cT4 13.8% (n Z 17), cN2 26.8% (n Z 33) and low-lying tumor (5 cm from anal verge) 24 .4% (n Z 30). Five year OS and DFS were 63.9% and 68.3% respectively. Among 112 patients who received TME, 108 (96.4%) had microscopic clear resection (R0). Twelve and 32 individuals had pathological complete response and ypT0-2N0, respectively. Five local recurrences (4.5%) were detected. The incidence of grade 3 or above acute and late radiotherapy toxicity was 8.1% and 12.2% respectively. After multivariate adjustment, positive circumferential resection margin (CRM) status on pathology report was found to be significant factor for worse OS and DFS.
Introduction
In the last two decades we have witnessed the evolution in the management of rectal cancer. Though surgery is still the most important treatment, the management has changed profoundly and is more relied on the contributions from other colleagues, like oncologists, radiologists and pathologists. Best clinical management is nowadays increasingly delivered by an expert multidisciplinary team (MDT).
Surgery is the primary treatment of localized rectal cancer, but conventional resections had been associated with local recurrence rate up to 25e40%. Local relapse has been much reduced after introduction of total mesorectal excision (TME), which is currently the gold standard procedure that reduced the rate of local relapse to less than 10% and increased the overall survival. 1, 2 Multiple randomized studies and meta-analyses have confirmed adding neo-adjuvant 3e8 or adjuvant radiotherapy 1,9e12 will improve the local control rate. Historically, some argued post-operative radiation is better as better selection of patients is possible according to the final pathological stage. However, in the Germany trial (CAO/ ARO/AIO 94) 5 that compared the preoperative and postoperative chemo-irradiation, the preoperative group had a significant decrease in local failure, acute toxicity, late toxicity, significant increase in sphincter preservation and no difference in five year survival. Since then, preoperative treatment is preferred in cT3/4 Nþ rectal cancer that required combined modality treatment.
For locally advanced rectal cancer (T3/4 or Nþ), there are two commonly used strategies: pre-operative short course radiation (PSCRT) (5 Gy per fraction, 5 fractions per week) followed by immediate surgery that usually carried out in around 1 week, and pre-op long course chemoradiotherapy (PLCRT) (1.8 Gy per fraction, 5 fractions per week, to a total dose of 45e50 Gy) and surgery was performed after 6e8 weeks of waiting time. Neither approach is superior in direct comparison, in terms of local control and overall survival. However, subgroup analyses have suggested that PSCRT is less effective individuals with predictive of positive circumferential resection margin (CRM) or low-lying tumor. In fact PSCRT followed by immediate surgery rarely induced tumor regression. Therefore, most authorities 13e16 have recommended PLCRT, either concurrent with 5-fluorouracil (5-FU) or capecitabine, 17 in patients with threatened or involved mesorectal fascia (MRF), tumor with adjacent organ invasion (cT4 stage) and low-lying tumor. Other high risk factors of local recurrence would also be taken into consideration, like cN2 disease (four lymph nodes), lateral pelvic lymph node (internal iliac or obturator lymph nodes) involvement and extra-mural vascular invasion (EMVI).
Magnetic resonance imaging (MRI) now becomes the impeccable tool for local staging. It defines the location of tumor and its relationship with MRF and adjacent structure. Nodal status and EMVI can also be assessed. Multiple studies have confirmed MRI is highly reliable in predicting CRM.
18e20 On the contrary, multi-slice computed tomography (CT) is inferior to MRI in local staging and CRM prediction. Therefore, pre-operative MRI assessment is now the gold standard in management of rectal cancer. Despite PLCRT is now the standard treatment of advanced rectal cancer worldwide, most series reported outcomes based on rectal cancer variably staged with MRI or CT; few local data is available, especially for those with MRI staging. Therefore, we set up a study to report the clinical outcomes of the 123 Chinese patients with locally advanced rectal cancer all confirmed with MRI and were treated with PLCRT.
Methods

Patients
For all biopsy proven rectal adenocarcinoma (15 cm from anal verge) in our hospital, we used high-resolution thinslice magnetic resonance imaging (MRI) of pelvis to assess its local staging; contrast computed tomography (CT) of thorax, abdomen and pelvis to look for any distant metastasis. All patients had advanced rectal cancer (T3/4 or Nþ) without distant metastasis (M0) was then referred to MDT clinic for discussion.
Our institutional protocol defined poor risk factors as follows: tumor extending to within 1 mm MRF (i.e. anticipated CRM threatened or involved); cT3 low lying tumor (within 5 cm from anal verge); tumor has adjacent organ involvement (cT4 stage) or cN2 disease (four lymph nodes). Patients possess one or more risk factors would be treated with PLCRT. The MDT assessed all patients' physical condition and organ function to confirm their fitness for treatment.
Data were collected retrospectively by performing review of medical records (hard copy and electronic patient records, pre-and post-treatment radiology, radiotherapy documentation, surgical notes, pathological reports and follow-up clinic records). The research ethics committee of our hospital approved our study.
Treatment
All individuals were scheduled to start chemo-irradiation in around 2 weeks after MDT clinic. Patients were simulated in the treatment position (lied prone with a full bladder) using the belly-board. Target volume was defined using the clinical and radiological information. All patients underwent CT planning and the gross tumor volume (GTV) included the primary tumor and any significant surrounding lymphadenopathy. Clinical target volume (CTV) includes GTV plus 2 cm margin and high-risk nodal area includes mesorectal, pre-sacral, internal iliac and obturator lymph nodes. Planning target volume defined as CTV þ 1 cm margin to account for the setup error and organ motion. Patients were planned using conformal technique in a four to five fields arrangement to include the PTV within the 95% isodose. A dose of 45e50.4 Gy in 25e28 fractions over 5e6 week was prescribed to the 95% isodose line; dose was escalated to 54e56 Gy by means of simultaneous integrated boost (SIB) in selected bulky T3 and T4 disease.
Concurrent chemotherapy regime, either in form of 5-fluorouracil (5-FU) intravenous bolus (500 mg/m 2 in Day 1e3 and Day 29e31) or capecitabine (825 mg/m 2 twice daily from first day till last day of radiotherapy), was selected according to patients' preference. Patients were monitored weekly for symptoms, performance status, peripheral blood cell counts, biochemistry and toxicities during the treatment.
We repeated MRI exam in around 6 weeks after the completion of chemo-radiation to evaluate treatment response. Then, we performed TME surgery (either anterior resection, or abdominoperineal resection at the discretion of surgeons) at around 8e12 weeks after completion of PLCRT.
MDT clinic will review patients' recovery and their pathology report within 4 weeks after operation. We started adjuvant chemotherapy after patients recovered from surgery. Regime of choice includes capecitabine (2500 mg/m 2 twice daily for 2 weeks) or CAPOX (oxaliplatin 130 mg/m 2 day 1 and capecitabine 2000 mg/m 2 twice daily for 2 weeks), both repeated every 3 weeks for 6 cycles. Patients' age, comorbidities, performance status, recovery from surgery, and final pathology stage were taken into consideration. According to our institutional protocol, combination chemotherapy CAPOX was offered to patients with ypNþ disease based on the subgroup analysis result of ADORE trial, 21 while capecitabine or 5-FU alone for patients with ypN0 disease.
Post-treatment follow-up included measurement of carcinoembryonic antigen (CEA) at every clinic visit. Patients were reviewed every three months for the two years, and then every four to six months in the third to fifth years. We arranged imaging if there was clinical suspicious of recurrence or increasing trend of CEA. Colonoscopic exam was performed once within three years and repeated another within five years. For those with incomplete colonoscopy before operation, we carried out first endoscopy within first year after surgery. Acute and late radiotherapy side effects were assessed according to according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0, and the Toxicity criteria of the Radiation Therapy Oncology Group and the European Organization for Research and Treatment of Cancer. Perioperative complications represented by rate of 30-day postoperative mortality and morbidity were also reported.
Statistical analysis
Data were analyzed using SPSS version 22.0. Survival data was calculated using the KaplaneMeier method. Overall survival (OS) was defined as the time of radiotherapy begins to death for any reason or the day of last follow-up. Disease free survival (DFS) was defined as time of commencement of radiotherapy to date of disease recurrence (distant metastasis or locoregional recurrence) or death from any cause, whichever occurred first or the day of last follow-up. Cox proportional hazards regression model was used to adjust for various factors. 22 
Results
Between 1st Jan 2009 to 30th Oct 2014, 123 consecutive rectal cancer patients who had pelvic MRI staging and had been selected for PLCRT were recruited. Table 1 presents patients' baseline characteristics. Median follow-up time was 1392 days (range: 48e2886). Median age of patients was 59 years (range from 27 to 79 years). Imaging defined high risk factors were as follows: total 76 patients (61.8%) with either threatened or involved MRF (1 mm); 17 patients (13.8%) were staged as cT4 disease with adjacent organ(s) invasion; 30 patients (24.4%) had low lying tumor; and 33 patients (26.8%) had cN2 disease (4 lymph nodes).
All but only two patients completed the planned course of chemo-radiation. Both of them refused treatment at 27 Gy and 39 Gy due to toxicity respectively. Median time from the end of chemo-radiotherapy to surgery was 77 days (interquartile range: 32 days) with 117 individuals proceed to surgical operation. Total 110 patients with total mesorectal excision done (78 anterior resections, 25 abdominalperineal resection and nine with other operations). Seven were found to have inoperable disease at laparotomy. KaplaneMeier estimates of survival probabilities for patients who received TME exhibited a better OS and DFS rates compared with no TME (see Supplementary Fig. 1 ). Quality of TME was available in 49 patients, of which 47 (95.9%) had mesorectal fascia plane excision and two (4.1%) had intramesorectal plane dissection. Among 34 patients with tumor 5 cm from anal verge, 32 had surgery (two had inoperable disease at laparotomy). 15 (46.9%) patients had anterior resection and 17 (53.1%) had abdominal-perineal resection. But whether sphincter preservation surgery was performed also depended on age, co-morbidities, tumor bulkiness and surgical expertise. The combined incidence of grade 3 or above acute radiotherapy toxicity to the skin, bowel, and urinary toxicity was 8.1%. The combined incidence of grade 3 or above late radiotherapy toxicity to the bowel, and urinary tract was 12.2%. For grade 3 or above acute chemotherapyrelated toxicity, the incidences of neutropenia, anemia, and thrombocytopenia were 8.9%, 2.4%, and 0%, respectively. The most common non-hematological grade 3 or above acute toxicity was diarrhea (5.7%). With regard to surgical complications, 13 (10.6%) patients had delayed wound healing, 12 (9.8%) had anastomotic leakages of different grades, six (4.9%) had post-operative ileus. There was no 30-day postoperative mortality reported.
Among patients who had TME, 96 (87.3%) received adjuvant chemotherapy. For 14 (12.7%) patients without initiation of adjuvant systemic treatment, two due to patients' refusal, seven due to poor post-operative recovery or complications, three were medically unfit, one developed rapid disease progression, one due to both poor recovery and rapid disease progression. 96.4% (106/110) of the population undergoing TME surgery achieved microscopic clear resection (R0) and 90.6% (106/117) including for all who underwent operation. Four patients with involved CRM <1 mm (R1) at pathological specimen.
Among the 110 patients who had TME, 68 patients had information of their pathological grading of regression, 10.9% (12 out of 110) patients had pathological complete response (pCR). 25.5% (28 out of 110) had only microscopic foci, while the remaining 28 (25.5%) reported with no tumor regression.
The distribution of MRI radiological and pathological response is highlighted in Table 3 . 67.3% (74 out of 110) patients had T-and/or N-downstaging, and 43.2% (32 out of 74) of them had significant downstaging after PLCRT, with pathological stage I disease (ypT0-2N0) (see Table 4 ). Around 46.4% (51/110) of tumors was over-staged when comparing post-PLCRT MRI re-staging versus final pathological staging.
33 of 110 patients who had received TME have had recurrent cancer and 26 have died of recurrence. One patient died of small cell carcinoma. One patient died of postoperative complication. Another two individuals died without proven cancer recurrence (cerebrovascular accident n Z 1, pneumonia n Z 1); causes of death were unknown in two patients.
Distant relapse was the commonest mode of failure, it occurred in 32 patients. Most common site of first recurrence was lung metastasis (n Z 20). Other sites of distant recurrence include liver metastases (n Z 12), peritoneal disease (n Z 5), para-aortic lymph nodes metastasis (n Z 8). Multiple sites of relapse were detected in 10 individuals. Five patients developed local pelvic recurrence, three patients presented with synchronous distant recurrence; one patient had peritoneal disease beforehand and developed metastasis at the pouch of Douglas; only one patient had isolated local relapse. Most of the recurrences were asymptomatic (n Z 25), which was detected by rising trend of CEA followed by subsequent imaging.
KaplaneMeier curves were performed to evaluate OS and DFS. Univariate and multivariate analysis using Cox regression model were used to adjust for different factors ( Table 2 ). Three year and five year OS were 77.2% and 63.9% respectively. Three year and five year DFS were 69.4% and 68.3% respectively (Fig. 1) Fig. 2A) . Univariate analysis revealed that the time from RT completion to surgery, presence of threatened CRM on final pathology, pathological T and N stage, and number of histologically involved lymph node could potentially influence DFS, but only threatened CRM (HR 8.36, 95% CI 2.31e30.24, pvalue Z 0.001) and pathological N stage (HR 1.83, 95% CI 1.11e3.01, p-value Z 0.018) remained significant after multivariate adjustment (Fig. 2B ).
Discussion
pCR rate was 10.9% and five year OS was 63.9%, though slightly less favorable but still is comparable to local 23 and international data.
6,24e26 All of our patients underwent pelvic MRI as part of their staging investigations, while other international and local series did not, or only offered to a portion of patients. Since MRI is standard in determining locoregional disease status now, we postulated that our data reflect prognosis more accurately in patients with T3 with risk factors, T4 and/or N2 disease, treated with neoadjuvant chemoradiation. Also, our cohort contained patients with advanced diseases, the inclusion criteria is also the reason for the different survival figures. Patients who received TME had better OS and DFS rates. It is likely that the number of patients who did not receive TME was too small to draw definitive conclusions from these findings. Nevertheless, our result showed that the importance of good TME surgery that is compatible with current evidence.
Together with the downstaging effects, the completion resection rate was high (96.4%), which is most important for cure in rectal cancer. CRM status is prognostic factors for OS and DFS, it remains significant after multivariate adjustment. Studies have shown CRM involvement is an independent prognostic factor, it not only predicts local recurrence, but also distant metastasis and overall survival. 27 In our cohort, local recurrence was low in both groups, however, patients with CRM involvement were more commonly associated with distant metastases and that is accounted for poorer DFS & OS. It is in line with the current literature. We could not find association between time from chemoradiation completion to surgery and outcome, likely due to the sample size. The benefit of adjuvant chemotherapy in rectal cancer is controversial, especially after PLCRT and definitive rectal operation. The long term result from EORTC 22921 28 showed that adjuvant chemotherapy with 5-fluorouracil (5-FU) and folinic acid after preoperative radiotherapy (with or without chemotherapy) did not affect DFS or OS in cT3-4 resectable rectal cancer. Similar findings were detected in other trials, using 5-FU based 29 or oxaliplatin based adjuvant chemotherapy. 30 However, studies have shown that adding oxaliplatin to adjuvant 21 and/or neoadjuvant 31 treatment can improve DFS. In our study, completion of adjuvant chemotherapy at full dose was not a prognostic factor. This highlights the importance of future research, preferably in prospective manner, to assess the benefit of adjuvant chemotherapy in this context.
Pelvic MRI is standard staging modality in rectal cancer. In our series, all our patients underwent MRI as part of initial staging, this ensured the accuracy of our staging. However, it was not uncommon we encountered the problem of over-staging in the post-PLCRT MRI. There are reports suggesting that post-PLCRT MRI is often unable to differentiate between viable tumor, residual fibrotic nontumor tissue, and desmoplastic reaction, resulting in poor agreement between post-PLCRT MRI and pathologic staging in both T and N stages. 32 In our data, a significant portion of patients were over-staged by post-PLCRT MRI re-staging. On the other hand 67.3% patients responded to PLCRT by RECIST criteria (T-downstaging, N-downstaging and T-/Ndownstaging). These figures are compatible with modern series. However, our follow up time was long, we could reliably report late toxicity. Our study had certain limitations. Our data were collected retrospectively, there could be selective bias and other unknown confounding factors. Toxicity data and comorbidities were not systematically recorded, this may lead to inadequate statistical adjustment. Our sample size limited the ability to adjust for potential confounding factors and long term toxicity requires longer follow up to conclude.
Conclusion
The clinical outcomes of PLCRT in our institution are comparable with those in western literature. Our MRI staging lends support to the validity of data. CRM status is the most significant prognostic factor in OS and DFS, after multivariate adjustment.
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